JP2004315496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004315496A5 JP2004315496A5 JP2003206492A JP2003206492A JP2004315496A5 JP 2004315496 A5 JP2004315496 A5 JP 2004315496A5 JP 2003206492 A JP2003206492 A JP 2003206492A JP 2003206492 A JP2003206492 A JP 2003206492A JP 2004315496 A5 JP2004315496 A5 JP 2004315496A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- optionally substituted
- compound according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229940122344 Peptidase inhibitor Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VHNILDKAFINLSQ-UHFFFAOYSA-N 1-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazine-2,5-dione Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(N3C(CNC(=O)C3)=O)C=C2C=1C1=CC=C(C)C=C1 VHNILDKAFINLSQ-UHFFFAOYSA-N 0.000 description 1
- OXSMXKYERKHTMN-UHFFFAOYSA-N 4-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazin-2-one Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(N3CC(=O)NCC3)C=C2C=1C1=CC=C(C)C=C1 OXSMXKYERKHTMN-UHFFFAOYSA-N 0.000 description 1
- PEGVEDZUHHLCFU-UHFFFAOYSA-N 5-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]oxypentanoic acid Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(OCCCCC(O)=O)C=C2C=1C1=CC=C(C)C=C1 PEGVEDZUHHLCFU-UHFFFAOYSA-N 0.000 description 1
- 0 CC1=CCc2c(**)c(IN)c(**)nc2CCCCC1 Chemical compound CC1=CCc2c(**)c(IN)c(**)nc2CCCCC1 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003206492A JP4542757B2 (ja) | 2002-08-08 | 2003-08-07 | 縮合複素環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002231950 | 2002-08-08 | ||
| JP2003051575 | 2003-02-27 | ||
| JP2003206492A JP4542757B2 (ja) | 2002-08-08 | 2003-08-07 | 縮合複素環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004315496A JP2004315496A (ja) | 2004-11-11 |
| JP2004315496A5 true JP2004315496A5 (enExample) | 2006-08-17 |
| JP4542757B2 JP4542757B2 (ja) | 2010-09-15 |
Family
ID=33479505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003206492A Expired - Fee Related JP4542757B2 (ja) | 2002-08-08 | 2003-08-07 | 縮合複素環化合物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4542757B2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| JP2006232819A (ja) * | 2005-01-25 | 2006-09-07 | Takeda Chem Ind Ltd | シアノジヒドロピリジン化合物の製造方法 |
| BRPI0609352A2 (pt) * | 2005-03-04 | 2011-10-18 | Merck & Co Inc | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para tratar uma ou mais doenças, distúrbios ou condições, e para tratar diabetes melito não dependentes da insulina (tipo 2) em um paciente |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
-
2003
- 2003-08-07 JP JP2003206492A patent/JP4542757B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004315496A5 (enExample) | ||
| RU2007135339A (ru) | Производные пиридилуксусной кислоты | |
| JP2005112864A5 (enExample) | ||
| EP2371811A3 (en) | Azetidinecarboxylic acid derivative and medicinal use thereof | |
| JP2011502958A5 (enExample) | ||
| WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
| RU2005114021A (ru) | Производные имидазола и их применение в качестве периферически-селективных ингибиторов дофамин-бета-гидролазы | |
| RU2010126056A (ru) | Органические соединения | |
| JP2011504903A5 (enExample) | ||
| WO2001081312A3 (en) | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore | |
| JP2005539088A5 (enExample) | ||
| EA200900821A1 (ru) | Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv) | |
| JP2005508923A5 (enExample) | ||
| JP2007507494A5 (enExample) | ||
| PT2420491E (pt) | Compostos de piperidina 3,5-substituída como inibidores de renina | |
| NO20070088L (no) | 1-, (3R)-amino-4-(2-fluor-fenyl)-butyl !-pyrrolidin-(2R)-karboksylsyre-benzyl amin derivater og beslektede forbindelser som dipeptidyl-peptidase IV (DPP??IV) inhibitorer for behandling av type 2 | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| JP2004524279A5 (enExample) | ||
| RU2007116987A (ru) | Новые соединения | |
| JP2014511865A5 (enExample) | ||
| WO2006125621A8 (en) | Substituted piperidines as renin inhibitors | |
| WO2004106299A8 (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| JP2005510468A5 (enExample) |